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Abstract
Cell transplantation has been extensively studied to treat spinal cord injury (SCI). 
Various kinds of cell have been used as transplants. The most promising transplants 
are autografts, in which transplantable cells should be derived from adult tissues. In 
this respect, bone marrow stromal cells (BMSCs), adipose-derived stem cells (ADSCs), 
and skin-derived stem cells (SDSCs) are appropriate candidates as transplants for 
SCI. In fact, BMSCs have been extensively studied as a promising transplant for the 
treatment of SCI. Several studies have been reported concerning the effects of 
transplanting ADSCs and SDSCs for SCI. On the other hand, embryo-derived or 
genetically altered cells are associated with marked ethical and tumorigenic 
concerns. In the present review, we focus on cell transplants that are easily 
obtainable from adult tissues, and readily applicable for SCI. We think that only 
those cells that can be used as transplants for clinical cases have a meaning in 
regenerative medicine.
Introduction
 Generally, peripheral nerve fibers can re-
generate very well, whereas central nerve 
fibers cannot. This difference in the ability to 
regenerate posed a serious problem regarding 
the central nervous system (CNS). It had been 
generally believed that, unlike axonal regen-
eration in the peripheral nervous system 
(PNS), neurons in the CNS could not produce 
axonal sprouts following injury. However, 
Cajal's study clearly showed that this was not 
true: CNS axons had the ability to produce 
regenerating sprouts, which, however, cannot 
elongate further through a lesion in the CNS 
(Cajal, 1928). This is the reason why nerve 
regeneration cannot occur in the CNS. Why 
are axonal sprouts produced at the injured 
stumps unable to elongate in the CNS
 environment? What is the difference in the 
microenvironment between the PNS and 
CNS ? The major difference in the PNS and 
CNS may be tissue structures: there are 
extracellular matrices called endoneurium in 
the spaces surrounding individual nerve fibers 
in the PNS, whereas no such distinct extra-
cellular matrix is present in the CNS. Cellular 
components including myelinated axons are 
tightly packed without intervening collagen 
fibril-containing extracellular matrices in the 
CNS. This might be a major difference con-
tributing to the ability of axons to regenerate 
following nerve injury in the CNS. 
 On the other hand, it has been recognized 
that extracellular matrices serve as a scaffold 
for the outgrowth of regenerating axons in the 
PNS: regenerating axons extend through the 
collagen  fibril-containing extracellular matri-
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ces as well as along the inner surface of 
Schwann cell basal laminae (Ide et al., 1983). 
 Cell therapy for spinal cord injury began 
with the study of peripheral nerve segment 
transplantation into the spinal cord and 
medulla oblongata in the rat (David and 
Aguayo, 1981). Neurons located within the 
spinal cord and medulla oblongata emanated 
regenerating axons and extended over a long 
distance through the implanted peripheral 
nerve segments. This study clearly demon-
strated that axons of the CNS can regenerate 
in an appropriate environment just as in 
peripheral nerve segments. 
 Various kinds of cell have so far been used 
as transplants for cell therapy in spinal cord 
injury, including Schwann cells (Xu et al., 
1999; Golden et al., 2007; Someya et al., 2008), 
cultured cerebellar neurons (Shimizu, 1983), 
embryonic spinal cord tissue (Iwashita et al., 
1994), olfactory ensheathing cells (Li et al., 
1997; Ramon-Cueto, 2000; Plant et al., 2003), 
macrophages (Rapalino et al., 1998; Knoller et 
al., 2005), choroid plexus epithelial cells (Ide et 
al., 2001; Matsumoto et al., 2003), ES cells 
(McDonald et al., 1999), and bone marrow 
stromal cells (Wu et al., 2003; Hofstetter et al., 
2002; Ohta et al., 2004; Himes et al., 2006, Lu et 
al., 2007). 
 As Schwann cells play a major role in axonal 
regeneration in the PNS, it is reasonable to use 
Schwann cells as transplants for axonal 
regeneration in spinal cord injury (SCI). In 
fact, implanted Schwann cells facilitated 
axonal regeneration in SCI. However, the 
problem was that regenerated axons could not 
extend further into the host spinal cord tissue: 
regenerating axons could not extend beyond 
the lesion into the host spinal cord. This 
means that regenerating axons might not 
form a neural connection with the host 
nervous system, suggesting an absence of a 
contribution to functional improvement. 
Various techniques have been studied to make 
regenerating axons extend further beyond the 
border of the lesion; however, there is no 
effective way to overcome this problem. 
 Cultured neurons had been studied as 
transplants for SCI before the advent of the 
current large-scale cell therapy for SCI. The 
classical transplantation study of cultured 
neurons was performed about 30 years ago by 
Shimizu and colleagues (Shimizu, 1983), who 
transplanted cultured cerebellar neurons into 
spinal cord lesions of dogs. They assessed the
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effects of cell transplantation by observing the 
locomotory behaviors of the dogs as well as 
histological findings of spinal cord lesions. 
The basic concept of their study was the same 
as that of the current cell transplantation 
study. 
 Olfactory ensheathing cells (OECs) have 
been extensively studied. They are already 
used for clinical cases in some countries (Lima 
et al., 2006). OECs surround olfactory nerve 
axons, as in the case of Schwann cells in the 
PNS. Olfactory neurons characteristically 
retain the ability to regenerate, even in adults. 
Newly produced neurons emanate regenerat-
ing axons that can extend through the scaf-
folds of OECs into the olfactory bulb. This 
means that OECs provide suitable pathways 
for regenerating axons to extend from the PNS 
to CNS environments, indicating that OECs 
have the dual functions of Schwann cells and 
astrocytes. Owing to this characteristic dual 
property, OECs are believed to support the 
growth of regenerating axons in the SCI. 
OECs have already been applied to clinical 
cases in some countries; however, the clinical 
outcomes have not been sufficiently evaluated 
to verify the hypothesis that olfactory en-
sheathing cells are in fact involved in the 
facilitation of regenerating axon growth in 
SCI. 
 Choroid plexus epithelial cells are a conti-
nuation of ventricular ependymal cells. The 
grafting of choroid plexus tissue segments in-
duced vigorous axonal outgrowth within the 
spinal cord lesion. This suggests that choroid 
plexus epithelial cells (CPECs) might be used 
as transplants for the treatment of SCI. It 
should be noted that CPECs are a type of glial 
cell. Our previous study demonstrated that 
neural stem cells can be produced from CPECs 
in vitro (Itokazu et al., 2006). This means that 
CPECs might be a rare neural tissue from 
which adult neural stem cells can be produced, 
that are available for cell therapy in SCI. 
 The role of macrophages in spinal cord 
regeneration has been extensively studied 
from immunological perspectives by an Israeli 
group. The concept of their study was to 
utilize immunological reactions in SCI; they 
studied transplantation of activated macro-
phages. The clinical application of macro-
phages to SCI was planned, but no report on 
the outcomes of clinical cases has been 
published. 
 Embryonal tissues and ES cells involve  se-
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rious ethical problems regarding clinical ap-
plication. Even if the transplantation of these 
cells has had some beneficial effects on SCI in 
experimental animals, their clinical applica-
tion has been prohibited due to the associated 
serious ethical problem. Considering that the 
final goal of stem cell research for cell therapy 
is to apply research achievements for  the 
treatment of diseases, cells that cannot be  clin-
ically applied are useless and have no signifi-
cance in regenerative medicine. Although 
many studies have been conducted, ES cells 
have not yet been applied to clinical cases. 
 On the other hand, iPS cells have been 
received with considerable interest as a dream 
stem cell free from ethical problems. iPS cells 
have been paid much attention as a promising 
type of stem cell for regenerative medicine 
including SCI treatment. However, there has 
been no scientific report so far on the use of 
iPS cells as transplants for SCI. There are 
many problems concerning iPS cells used as 
transplants for SCI. One of the problems is the 
tumorigenic property of iPS cells. Undiffer-
entiated iPS cells should not be present in the 
transplants. Any trace of undifferentiated 
cells in the transplants might cause tumor 
development in the host. This means that iPS 
cells should be completely differentiated 
before transplantation. For this purpose, an 
effective method should be established to fully 
differentiate iPS cells into neurons or glial 
cells. Another problem is that it is not known 
whether iPS-differentiated neurons can sur-
vive and truly promote axonal regeneration 
after transplantation in spinal cord lesions. No 
report is available concerning whether iPS-
differentiated neurons or glial cells are effi-
cient transplants in SCI. iPS cells are not nat-
ural cells, but are forcefully changed into 
undifferentiated cells, which may cause some 
unexpected adverse reactions disturbing the 
normal tissue functions in vivo. These disad-
vantages regarding clinical application lessen 
the value of iPS cells. It is critically important 
for stem cells in regenerative medicine to be 
able to be used for clinical cell therapy. The 
question of whether iPS cells could have real 
benefits in regenerative medicine should  be 
addressed. Stem cells for regenerative  medi-
cine should be safe and demonstrated to have 
beneficial effects in cell therapy. In this 
respect, stem cells derived from adult tissues 
are most desirable as transplants: they are 
normal cells residing in adult tissues, and  safe
for use as autologous transplants. 
 Recently, adult stem cells have been studied 
extensively. Adult stem cells include BMSCs, 
ADSCs, and EDSCs. They are available from 
adult tissues, and can be used as autologous 
transplants for cell therapy. These tissues are 
easily obtainable, and have none of the ethical 
problems seen with ES or iPS cells, suggesting 
that they are readily available for use in 
clinical cell therapy. All of these three types of 
stem cell are derived from non-nervous tissues. 
Nevertheless, they have been studied as 
transplants in SCI. BMSCs have been studied 
most extensively, and shown to have 
beneficial effects on spinal cord regeneration. 
 In the present mini-review, we would like to 
survey the recent trends in cell therapy using 
these adult stem cells in SCI.
Bone  marrow  stromal cells (BMSCs)
 We have been involved for several years in 
the study of BMSCs for SCI treatment. BMSCs 
are cultured from the bone marrow of adult 
rats, and are considered to contain a small 
population of stem cells. 
 We showed that BMSC transplantation im-
mediately after SCI reduced cavity formation 
and enhanced axonal outgrowth in the SCI 
lesion (Wu et al., 2003). Electron microscopy 
showed that transplanted BMSCs are located 
in the lesion, in which the extensive out-
growth of immature axons occurred in the 
extracellular matrices. 
 Next, we studied cell infusion through the 
cerebro-spinal fluid (CSF) in acute SCI. 
BMSCs were injected into the 4th ventricle. 
Injected BMSCs were transported by the flow 
of CSF to the spinal cord, and a few of them 
invaded the lesion, while many became 
attached to the surface of the spinal cord. In 
this experiment, the locomotory function 
improved, cavity formation was reduced, and 
host axons around the lesion were rescued 
from degeneration (Ohta et al., 2004). Based on 
the fact that, although only a few of them 
invaded the lesion, BMSCs promoted the 
repair of the injured spinal cord, it was 
suggested that BMSCs might secrete some 
effective substances, which can be transported 
through the CSF to the lesion. Such 
substances might function to rescue affected 
axons from degeneration, and facilitate axonal 
regeneration in the SCI. Based on this study, 
and verifying the safety of injecting BMSCs
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into CSF of a monkey, we proceeded to the 
clinical application of BMSC injection through 
the CSF in a patient with acute SCI (Saito et  al., 
2008). Five patients have so far been treated 
by BMSC injection into the CSF via lumbar 
puncture. Mononuclear cells derived from the 
bone marrow have almost the same effects on 
 SCI as BMSCs (Yoshihara et al., 2007). 
 Recently, we studied the effect of BMSC 
transplantation on subacute SCI (Ide et al., 
2010). Rats were crush-injured at the Th 8-9 
level by dropping a 10—g metal rod onto the 
exposed spinal cord. Two weeks later, BMSCs 
were transplanted by injecting them directly
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into the lesion. It was shown that, even if 
BMSCs disappeared from the spinal cord, there 
was extensive axonal outgrowth through the 
extracellular matrices within the spinal cord. 
Cavity formation was markedly reduced, and 
the locomotory behavior improved. This 
showed that BMSC transplantation might be 
effective even for subacute SCI. 
 This study showed that there was an exten-
sive induction of extracellular matrices in the 
spinal cord lesion. Axonal outgrowth occurr-
ed through such extracellular matrices. Rege-
nerating axons are immature, and surrounded 
by developing Schwann cells (Fig. 1). These
Fig. 1 Electron microscopy. One week after transplantation
a.b
 c-1.
c-2.
Epon section. A cell assembly (asterisk) presumed to be engrafted 
BMSCs is located in the dorsal part of the spinal cord. The border 
of host white matter is marked by a dotted line. Scale: 50  um 
Electron micrograph taken from the area dorsal to the cell assembly 
in "a". There are numerous unmyelinated immature axons (some 
are labeled "A") covered by cell processes (arrows) or a cell body  (S), 
suggesting that these axon-associated cells might be developing 
Schwann cells. These unmyelinated immature axons are considered 
to be regenerating axons, but not remaining host axons. Scale:  2,um 
Magnification of an axon bundle. Two axons (A) are surrounded by 
cell processes  (S) of developing Schwann cells with basal  laminae 
(arrows) on their surface. There are collagen fibrils (Co) around the 
nerve bundle. Scale: 500 nm 
A developing Schwann cell  (S) covered by basal lamina (arrows) 
surrounds unmyelinated immature axons (A). Scale: 1  um 
(Reproduction from Ide et al., Brain Res., 2010)
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regenerating axons gradually developed to 
form myelin sheaths beyond 2 weeks post-
transplantation (Fig. 2). These features are 
similar to those seen in peripheral nerve re-
generation. It was unexpected that the  peri-
pheral nerve environment is formed within 
the spinal cord, through which nerve regene-
ration occurs. BMSCs might be involved in 
the induction of extracellular matrices, which 
form effective scaffolds for axonal outgrowth. 
In addition, it is probable that BMSCs secrete, 
as described above, some effective molecules 
to promote axonal survival and regeneration. 
 Numerous Schwann cells surrounded re-
generating axons. The source of these 
Schwann cells was unknown. One possibility 
was the dorsal roots located near the lesion. In 
this experiment, it might be less probable that 
regenerating axons came from the roots, 
because regenerating axons appeared to be 
continuous with the nerve fibers within the 
spinal cord. Schwann cells from the roots 
might migrate to the regenerating axons in 
the spinal cord. Another possibility is that 
there might be some Schwann cell sources 
within the spinal cord, but this remains to be 
demonstrated. The third possibility is the 
transdifferentiation of BMSCs into Schwann 
cells within the spinal cord. This might be 
rather unlikely because no Schwann cells were 
labeled by GFP, the cell marker for engrafted 
BMSCs. 
 The involvement of Schwann cells in axonal 
outgrowth within the spinal cord has been 
reported in several studies (Lu et al., 2007; 
Ankeny et al., 2004; Himes et al., 2006; 
Hofstetter et al., 2002). In addition, Lu et al. 
(2007) indicated the induction of extracellular 
matrices by showing the presence of NG2,  L1, 
and laminin employing immunohistochemist-
ry: NG2 might be related to proteoglycans of 
extracellular matrices,  L1 might be expressed 
on the contact of axons with Schwann cells, 
and laminin might be derived from the basal 
laminae on the surface of Schwann cells 
associated with axons. 
 Cavity formation was markedly reduced 
(Fig. 2). The spinal cord lesion was mostly 
filled with the proliferated extracellular 
matrices in the cell-transplanted rats. On the 
contrary, large cavities were formed in the 
lesion of the control. 
 The BBB score for the locomotory function 
was assessed by observing the behaviors of 
rats for 5  min in the open field. The behaviors
were recorded by video camera, and evaluated 
by 2 persons blinded to the experiment. BBB 
scores were about  9-10 in the transplantation 
group, while 5-6 in the control (Fig. 3). The 
difference of 4-5 points is marked. 
 The tissue condition of the spinal cord lesion 
might be markedly different between acute 
and chronic SCI. Cell transplantation in acute 
SCI can be performed experimentally, but is 
not practical in clinical cases. There might be 
glial scar formation around the cavity in 
chronic SCI. We thought that a subacute or 
chronic lesion in SCI might become separated 
by a glial scar from the CSF, suggesting that 
cells infused into the CSF may not be able to 
access the lesion. Therefore, we engrafted 
BMSCs directly into the lesion in this subacute 
SCI model. 
 Crush injury reflects the contusion injury of 
clinical SCI. Therefore, we usually employ 
crush injury in experiments. Transection 
injury cuts open the pia mater, leading to the 
exposure of spinal cord tissue to the  sur-
rounding extra-spinal cord tissues, resulting in 
infiltration of connective tissues into the 
spinal cord. 
 Our previous study indicated that trophic 
factors might play a major role in the repair of 
spinal cord injury. The trophic factors were 
considered to contribute to the survival of 
degenerating axons and the outgrowth of 
regenerating axons, as noted above. Several 
other studies suggested that BMSCs release 
diffusible neuroprotective factors (Chopp et 
al., 2000; Ankeny et al., 2004; Swanger et al., 
2005; Himes et al., 2006; Shintani et al., 2007). 
It has been shown that BMSCs release trophic 
factors including BDNF, VEGF, and cytokines 
such as IL-6 and stem cell factor (Neuhuber et 
al., 2005), and  IGF-1 (Ohtaki et al., 2008). We 
examined the effect of conditioned medium 
(CM) of BMSC culture. The CM has a potent 
effect on neuronal survival and  neurite 
extension. Biochemical analysis revealed that 
the CM contains various trophic factors 
including those above-mentioned. However, 
bioassay analysis showed that individual 
factors or their combinations did not have the 
same effects as the CM on neuronal survival 
and  neurite extension.
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Fig. 2 Electron microscopy of axons extending through the lesion at 2 and 8 
weeks (a and b), and reduction in cavity formation at 8 weeks after BMSC 
transplantation (c, d and e) 
a. Two weeks after transplantation. Individual axons (A) are covered by 
  Schwann cells (S). Some are myelinated. Scale: 5  um 
b. Eight weeks after transplantation. Individual axons (A) are thickly 
  myelinated by Schwann cells  (S). Scale: 10  um 
c. Horizontal section of the spinal cord following BMSC transplantation. 
  The lesion (arrow) is filled with tissues. HE staining. 
d. Control. Vehicle injection. Cavities (asterisks) are formed in the lesion 
  (arrow).  HE staining. Scale: 2 mm (c and d) 
e. This graph shows a comparison of the volume of the spinal cord cavity 
  between control and BMSC transplantation groups. The difference is 
  significant (asterisk,  P  < 0.01). 
  (Reproduction from Ide et al., Brain Res., 2010)
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Fig. 3 Locomotory behavior 
This graph shows BBB scores in rats of cell transplantation and control 
groups  1  weeks after injury (8 weeks after cell transplantation). There 
are significant differences  (P< 0.05) between cell transplantation and 
control groups 2, 4, and 8 weeks after BMSC transplantation (asterisks). 
(Reproduction from Ide et al., Brain Res., 2010)
Adipose-derived stem cells (ADSCs)
  Adipose tissue is mesenchymal, distributing 
as a component of connective tissues. It has 
recently been demonstrated that adipose tis-
sue contains stem cells which can transdif-
ferentiate into osteocytes, chondrocytes, and 
even neural cells including neurons and glial 
cells in vitro (Safford et al., 2002, 2004). Saf-
ford et al. (2002) cultured ADSCs in medium 
containing butylated hydiroxyanisole, val-
proic acid, forskolin, hydrocortisone, and 
insulin, and observed the differentiation of 
ADSCs into cells with a neuron-like mor-
phology. They presented data from immuno-
histochemistry and immunobotting, showing 
that the neuron-like cells expressed neuronal 
markers including MAP (myelin associate 
protein), GFAP, and GAP-43 (growthas-
sociated protein). However, it was suggested 
that ADSCs changed into neuron-like cells due 
to cellular damage in medium containing 
several unusual factors for cell differentiation. 
 Huang et al. (2007) studied the differentia-
tion of stem cells obtained from the adipose 
tissues of facial and abdominal subcutaneous 
regions. ADSCs are positive for CD29, CD44, 
and CD 90. They described that ADSCs were 
differentiated into osteocytes, chondrocytes, 
and neurons in vitro. They presented data on 
immunohistochemistry and immunobotting,
as in the paper of Safford et al. (2002, 2004). 
 Although it is generally accepted that 
ADSCs differentiate into osteocytes and 
chondrocytes, whether ADSCs differentiate 
into neurons is controversial. Transdiffer-
entiated neurons should be identified not  only 
based on morphological and immunohisto-
chemical data, but also by electrophysiological 
characteristics. 
 An early transplantation study of ADSCs 
showed effective results regarding spinal cord 
regeneration (Kang et al., 2006). 
 Tapp et al. (2009) highly evaluated adult 
tissue-derived stem cells including BMSCs, 
ADSCs, and SDSCs which were easily avai-
lable, and used clinically in regenerative 
medicine. They studied the differentiation of 
stem cells from adipose tissues of the facial 
and abdominal subcutaneous regions. Various 
surface antigens have been used for the 
characterization of these mesenchymal stem 
cells: CD73 (surface enzyme),  CD90 and  CD105 
(both are extracellular matrix protein), And 
CD 29 (integrin). On the other hand, hemato-
poietic markers such as CD45, CD34,  CD14, CD 
 11b, and  CD19 are not present on mesen-
chymal stem cells. They used scaffolds such 
as collagen fibrils, chitosan, gelatin, chond-
roitin sulfate, and alginate for the differ-
entiation of ADSCs into osteocytes, and 
chondrocytes. No clear marker criteria to
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differentiate between ADCs, BMSCs, and 
fibroblasts are currently available. 
 Rhu et al. (2009) performed the allogeneic 
transplantation of ADSCs derived from adult 
dogs into SCI produced by epidural balloon 
compression 1 week before transplantation. 
ADSCs were positive for CD 44, 90, and 105, 
but negative for CD 14, 34, and 45. 
 Five to nine weeks after transplantation, 
dogs showed an improved locomotory func-
tion. Cavity formation was reduced, and 
extensive axonal growth occurred in the 
lesion. They indicated that ADSCs might be 
transdiffferentiated into astrocytes, neurons, 
and oligodendrocytes. MRI pictures and 
corresponding HE sections were shown in 
parallel, indicating that T2—wighted MRI 
reflects the CSF in the subarachnoidal space 
and cavities. This study did not clearly 
describe how transplanted ASDCs contributed 
to axonal outgrowth and caused functional 
recovery. 
 Zhang et al. (2009) obtained neurospheres 
from subventricular CNS tissue and even from 
non-nervous tissues including ADSCs and 
BMSCs by culturing in medium containing 
EGF (epidermal growth factor) and bFGF 
(basic fibroblast growth factor) for 5-7 days. 
They were transdifferentiated into neurons, 
astrocytes, and oligodendrocytes. Astrocytes 
were the most abundant, followed by neurons 
and oligodendrocytes. These neurospheres 
were implanted directly into the lesion 1 week 
after SCI. Locomotory functions were im-
proved, and cavity formation was reduced, 
with the highest effectiveness shown by 
neurospheres from the subventricular zone, 
followed by BMSCs and ADSCs. They used 
BrdU for cell labeling, which could label host 
cells, leading to the misinterpretation of the 
fate of transplanted cells in vivo. How axonal 
outgrowth occurred in the lesion and how 
regenerated axons interacted with the host 
neural networks were not clarified in this 
study. 
 The  transdifferentiation of engrafted cells 
might not be a major problem. The most 
important question is how cell transplantation 
induces axons to regenerate in the lesion, and 
extend further into the host tissue to form 
efficient connections with the host neural 
networks in SCI. No study has focused on this.
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C1' • Skin-derived stem cells  (SDSCs)
 The skin consists of two components, the 
epidermis and dermis. The cells in the epi-
dermal basal layer continue to be proliferative 
even in adults. In addition, hair follicles 
contain proliferative cells which contribute to 
the hair cycle and to epidermal regeneration as 
a source of stem cells in the severe skin lesions. 
It has been demonstrated that SDSCs come 
almost exclusively from hair follicles includ-
ing the bulge located near the sebaceous gland 
and dermal papilla at the bottom. It should be 
noted that these stem cells can be regarded as 
a lineage of neural crest cells. 
 Multipotent neural crest cells have been 
identified at other sites including the spinal 
and sympathetic ganglia (Duff et al., 1991), and 
the gastrointestinal tract (Kruger et al., 2002). 
 Hoffman (2006) described the hair follicle 
bulge as an abundant, easily accessible source 
of actively growing pluripotent adult stem 
cells, expressing nestin, that differentiate into 
neurons, glial cells, keratinocytes, and smooth 
muscle cells in vitro. In his experiment, hair 
follicle stem cells that had been implanted into 
the gap regions of a severed sciatic nerve 
transdifferentiated into Schwann cells, which 
markedly enhanced the rate of nerve re-
generation and restoration of nerve functions. 
 Yu et al. (2006) demonstrated multipotent 
stem cells in hair follicles including the bulge, 
using the medium for the culture of human ES 
cells. These cells express ES cell markers 
including Nanog and Oct4, as well as neural 
crest cell markers. 
 They obtained cell spheres from hair 
follicles, and cultured them attached to the 
culture dish, from which melanocytes, neu-
rons, and smooth muscle cells were differ-
entiated in the differentiation medium specific 
for each cell type. 
 Sieber-Blum et al. (2004, 2006) explanted 
bulges from adult mouse whisker follicles to 
produce clonal cells, including neurons, 
smooth muscle cells, Schwann cells, and 
melanocytes. SDSCs differentiated into 
Schwann cells due to the presence of neu-
regulin-1, and into chondrocytes due to bone 
morphogenetic protein-2. They concluded 
that epidermal neural crest cells are promising 
candidates for diverse cell therapy paradigms 
because of their high degree of inherent 
plasticity and due to their easy accessibility in 
the skin.
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  Hunt et al. (2008) described the hair follicle 
 dermal papilla as a niche of precursor cells 
with neuronal and glial potential. They used 
the Wnt-1—cre/R26R mouse, in which neural 
crest cells can be identified by immuno-
histochemistry for   -galactosidase. Neural 
crest cells expressed Pax3 and slug. Cell 
spheres obtained from dermal papillae were 
cultured in medium containing BDNF, BGF, 
NT-3, retinoic acid, and FGF-2 to induce 
differentiation into neuronal cells. For 
Schwann cell differentiation, cell spheres were 
cultured in medium containing neuregulin 
and forskolin. They demonstrated that neu-
ronal and glial cells were also produced from 
human hair follicles in the facial skin. 
  Sieber-Blum and Hu (2008) described in 
their review article that epidermal neural crest 
cells (i. e., SDSCs) have the genes c-Myc, Klf4, 
Sox2, and Lin28, similar to those in iPS cells. 
Oct4 and Nanog are present at very low levels 
in epidermal stem cells. These two genes are 
considered to be responsible for the tumori-
genic property of these cells following trans-
plantation. They emphasized that the low 
content of these genes indicated the low 
tumorigenic potential of neural crest stem 
cells. 
  Hu et al. (2006) demonstrated the molecular 
characteristics of epidermal neural crest stem 
cells by identifying  19 genes representative of 
epidermal neural crest stem cells. 
 Wong et al. (2006) showed that SDSCs from 
face whisker follicles had asphere-forming 
potential and exhibited multipotential pro-
perties, while those from hair follicles in the 
trunk skin were restricted to the glial and 
melanocyte lineages. Sphere-forming SDSCs 
from adult mouse skin displayed a rather 
restricted potential in vivo. SDSC spheres, 
when dissociated and injected into the lateral 
ventricles of rat and chicken embryos, 
remained largely undifferentiated as cell 
aggregates close to the injection site, and 
failed to integrate into the host central 
nervous system tissue. This is in contrast to 
neural progenitors obtained from ES cells or 
neural stem cells from the CNS. The authors 
did not observe neural differentiation, tissue 
integration, or behavioral improvement upon 
the transplantation of SDSCs into the striatum 
of a 6—hydroxydopamine-lesioned mouse 
model for Parkinson disease, or on intravenous 
injection into mice with experimental auto-
immune encephalomyelitis. These trials
suggest that SDSCs from adult skin, when 
transplanted into the CNS, cannot transdif-
ferentiate into neural cell types in the CNS. 
  Biernaskie et al. (2007) used murine SDSCs 
for transplantation. SDSCs were different-
iated into Schwann cells (SDSC-SC) before 
transplantation. In addition, they prepared 
neural stem cells (NS) derived from the 
forebrain subventricular zone. They corn-
pared the effects of SDSC-SC, SDSCs, and NS 
on spinal cord regeneration by transplanting 
them into a rat spinal cord lesion. SDSC-SC 
and SDSCs promoted the recruitment of 
endogenous Schwann cells into the lesion. 
They showed that SDSC-SC transplantation 
was the most effective for axonal regene-
ration, cavity reduction, and improvement of 
the locomotory function. They also indicated 
the changes in extracellular matrices by 
immunohistochemistry for neurocan and 
laminin. Axonal outgrowth was shown by 
immunohistochemistry for serotonin (5HT), 
calcitonin gene-related protein (CGRP), and 
tyrosine hydroxylase (TH). There is no clear 
description concerning how axonal regene-
ration was facilitated by cell transplantation. 
Their study suggests that regenerating axons 
surrounded by both endo- and exogenous 
Schwann cells grew through extracellular 
matrices; however, there is no statement 
regarding this consideration. It is interesting 
to compare the effects of NS with those of 
SDSC-SC and SDSCs involving a comparison 
between neuronal and non-neuronal cells. 
However, no description concerning the 
comparison of these cells was given in their 
study.
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